Response by Fauchier et al to Letter Regarding Article, “Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA2DS2-VASc Risk Factor Be Anticoagulated?”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
We thank Zhang et al for their interest in our study reporting a positive net clinical benefit of oral anticoagulation using vitamin K antagonist for preventing stroke and other thromboembolic events in atrial fibrillation patients with only 1 nongender-related stroke risk factor (CHA2DS2-VASc 1 in males or 2 in females).1
Recent trials with non-vitamin K antagonist oral anticoagulant (NOAC) agents provide data for benefit even with at …